Phaseline

Companies › Canwell Biotech

Canwell Biotech: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CAN016–Phase 1Patients With Advanced Solid TumorsDec 2028
CAN1012
selective TLR7 agonist
–Phase 1Solid Tumor; Ductal Carcinoma in Situ–
CAN2109–Phase 1Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06332430CAN2109Phase 1Solid TumorOncologyMay 2025
NCT05580991CAN1012Phase 1Solid TumorOncologyJun 2025
NCT07664150CAN016Phase 1Patients With Advanced Solid TumorsOncologyDec 2028
NCT07408856CAN1012Phase 1Ductal Carcinoma in SituOncologyMay 2030

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.